By Chris Wack
BioCryst Pharmaceuticals shares were down 12% to $8.08 after the company reported a fourth-quarter loss that was wider than expected.
The stock hit its 52-week high of $9.50 Friday, and is up 42% in the past 12 months.
The biotechnology company said it had a quarterly loss of $26.8 million, or 13 cents a share, compared with a loss of $61.7 million, or 31 cents a share, in the same quarter last year. Analysts polled by FactSet were looking for a loss of $13 million, or five cents a share.
Revenue for the quarter was $131.5 million, compared with last year's $93.4 million and the $130.1 million analysts were expecting.
The company said quarterly revenue for Orladeyo, its treatment for the prevention of hereditary angioedema attacks, was $124.2 million, 36.6% higher than last year.
BioCryst increased its 2025 revenue guidance for Orladeyo to $535 million to $550 million, from its previous estimate of $515 million to $535 million.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 24, 2025 10:59 ET (15:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。